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Introduction: It has been reported that platelets can eradicate tumor cells in vitro, although 
the mechanism of this effect has not been determined. The effect of platelets on the induction 
of apoptosis in tumor cells is largely unknown. 
Materials and methods: To investigate this effect, two human hematologic cell lines, K562 
and Daudi, were independently faced with unstimulated and thrombin-activated platelets. 
After the elapsed co-culture time, the levels of caspase-3 and CD95 were evaluated as a sign 
of cell death and apoptosis. In addition, immortalized cells were evaluated using trypan blue, 
7-AAD and WST-1 methods. 
Results: CD95 and caspase-3 levels were significantly increased in both cell lines compared 
with the control cells (P<0.05). Beside, considerably lower number of living cells were 
shown by trypan blue, 7-AAD and WST-1 in the treatment groups compared with the control 
group (P<0.05). 
Conclusion: This study demonstrated the role of apoptosis in tumor inhibition and implied 
the ability of platelets to induce apoptosis in tumor cell lines. 
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Introduction 
Platelets are blood cells that play the key 
role in hemostasis (1). They contain a 
large number of biologically active 
proteins in the cytoplasmic granules 
containing alpha and dense granules, 
primary lysosomes and peroxisomes (2). 
Platelets also have several 
immunologically important cytokines and 
chemokines that are released at the time of 
activation (3, 4). Alpha granules contain a 
number of important growth factors, 
including vascular endothelial growth 
factor (VEGF), platelet-derived growth 
factor (PDGF), epidermal growth factor 
(EGF) and transforming growth factor beta 
(TGFβ) that are effective in improving 
wounds and angiogenesis (5) Platelet-
derived VEGF not only facilitate the 
angiogenesis but also increase vascular 
permeability and the further spread of 
tumor cells (6). Beside, in addition to the 
effective factors of angiogenesis, platelets 
contain antiangiogenic factors such as 
PF4, TSP-1 and endostatin that can limit 
the growth and survival of cancer cells (7). 
This could reveal different roles of platelet 
secretory factors in pathophysiological 
process in the body. The anti-metastatic 
factor; PF4 can be as an available 
candidate in cancer therapy (8). Further 
investigations have revealed that the 
majority of tumor cells or the primary 
tumor tissues are able to produce soluble 
factors such as ADP and thrombin that 
could cause platelet activation as well as 
platelet or platelet-tumor aggregations (9-
10). Activated platelets and microparticles 
released from platelets included the 
functional adhesion receptors of P-selectin 
and CD40L (11, 12). At the time of 
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activation, platelets release two types of 
vesicles containing platelet microparticles 
and exosomes. Under the physiological 
conditions, these membrane vesicles are 
responsible for transmitting signals of 
platelets to other cells. Platelet-derived 
microparticles sprout from the membrane 
of activated platelets and have the 
membrane molecules of platelets such as 
CD40L that can react with cells containing 
CD40 receptor (13). The role of platelets 
in immune and inflammatory responses 
and defense against pathogens and 
malignancies is primarily occurring 
through several molecules, including 
TLR1, MHC-1, CD40 and CD40L (14).  
Platelets have different factors of cell 
growth induction or cell growth inhibition. 
After the co-culture of platelets with the 
neoplasm cells, platelets impose the cell 
growth inhibition effects using different 
mechanisms by cytotoxic effects (15, 16) 
or cell cycle preventing (17). Because of 
the lack of information in the field of 
apoptosis induction of platelets on tumor 
cells, we studied this issue using treatment 
of two cell lines with platelets or 
thrombin-activated platelets. 
Materials and methods 
Preparation of platelets: Five single 
donor platelet concentrate bags (JMS 
Singapore Plte Ltd. contained CPDA-1 
solution) were prepared from Iranian 
Blood Transfusion Organization (IBTO). 
Informed consent was obtained from the 
blood candidates by (IBTO). Platelets 
were centrifuged at 300g for 5 min to 
remove red blood cells (RBCs) and white 
blood cells (WBCs). The supernatant was 
centrifuged at 1200 g for 10 min to 
sediment platelets. Platelets were counted 
by an automated hematology analyzer 
(Sysmex K-1000, Kobe, 
Japan).Additionally; platelets were 
activated in the presence of thrombin 
(3U/ml) at room temperature. 
The cell lines: Two tumor cell lines were 
used in the present study, K562 (human 
chronic myelogenous leukemia cell line) 
and Daudi (human B Lymphoblast cell 
line) were provided by (NCBI) national 
cell bank of Iran, Pasteur Institute (Tehran, 
Iran). 
The co-culture of platelets and cell lines: 
Unstimulated and thrombin-activated 
platelets (5×107cells), were independently 
introduced into the culture medium 
included K562/ Daudi (1×105 cells) in the 
wells of a cell culture plate. The co-culture 
medium consisted of RPMI 1640 
supplemented with 10% FBS, 1% 
penicillin and streptomycin (GIBCO, 
USA), prepared from a stock solution of 
100 X concentration of 10,000 IU/mL 
penicillin and 10,000 µg/mL of 
streptomycin and 1% L-glutamine (200 
mM). The culture plates were incubated at 
37ºC for 48 hours in a humidified 
incubator with 5% CO2 atmosphere. It was 
worthy of note that all co-cultures were 
performed in duplicate in the presence of 
appropriate controls. Controls of this study 
consisted of K562 or Daudi cells without 
any treatment.  
7-AAD viability staining: 7-
Aminoactinomycin D (7-AAD) is a 
fluorescent intercalator that undergoes a 
spectral shift upon association with DNA. 
After the co-culture time, cells in each 
well were harvested and centrifuged at 
400g for 5 min to remove platelets. 
Deposited cells were washed once with 
assay buffer (Cayman 7-AAD assay kit, 
USA), resuspended in the staining solution 
of the kit and incubated at room 
temperature for 15 min at dark. Cells were 
centrifuged at 400 g for 5 min and 
suspended in assay buffer for analysis with 
flow cytometry technique. 
CD95 expression levels: The expression 
of CD95 was studied on K562 and Daudi 
cells after the co-culture time by flow 
cytometry technique. In a one-step 
method, 2 µl of FITC-conjugated mouse 
anti-CD95 antibody (eBioscience, USA) 
was added to the tubes each included 105 
cells in 100 µL. The tubes were left for 40 
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Active caspase-3 concentration: The 
experiment was based on the measurement 
of P17 subunit of active caspase-3 inside 
the human cells using ELISA method 
(Abcam, UK). Forthy-eight hours after the 
co-culture, K562 and Daudi cells were 
lysed by the extraction buffer included in 
the kit after the addition of the protease 
inhibitor (1 mM PMSF).The extracted 
protein solutions were stored at -80ºC. 
ELISA method was done as the 
manufacturer's instructions. 
WST-1 cell proliferation and viability 
assay: WST-1 is a method to measure the 
cell proliferation. Expansion in the number 
of viable cells results in an increase in the 
activity of the mitochondrial 
dehydrogenases, which in turn leads to 
increase in the amount of formazan dye 
formed. After the co-culture time, cells 
were centrifuged at 400 g to remove 
platelets. Afterwards, 10 µL of WST-1 
reagent (Cayman cell proliferation assay 
kit, USA) was added to each well 
containing 100 µL of cells in a 96 well 
plate. Subsequently, the plate was 
incubated for 4 hours at 37ºC. The 
absorbance of wells was measured with a 
microplate absorbance reader at the 
wavelength of 450 nm. 
Trypan blue exclusion test of cell 
viability: Trypan blue provides the 
possibility for detection of live and dead 
cells, microscopically. After the end of co-
culture time, the number of viable and 
dead cells was enumerated for the cells of 
each well by trypan blue. Finally, the 
percent of dead cells was calculated. 
Statistical analysis 
The non-parametric; Wilcoxon method 
with SPSS 16.0 software was used to 
compare the results of this experiment. 






Figure 1. K562 and Daudi cell lines were treated with platelets (plt) or thrombin-activated platelets (aplt), in the 
24-well culture plates. Dead cells were labeled with 7-AAD dye and measured by flow cytometry technique. 






































7-AAD viability staining results: The 
percent of 7-AAD-stained cells was 
measured by flow cytometry technique 
(Figure 1) and showed significantly greater 
amounts in the two treatment groups than 
control group (P<0.05). 
CD95 expression: CD95 (FAS) 
expression was analyzed on K562 and 
Daudi cells after 48 hours of co-culture 
using the flow cytometry technique. 
Significantly higher expression of CD95 
was detected in the treatment groups 
compared with the untreated control group 
(P<0.05) (Figure 2).  
Active caspase-3 concentration: The 
concentration of human active caspase-3 
was significantly increased in the extracts 
of K562 and Daudi cells after the co-
culture time compared with the control 
group (P<0.05) (Figure 3). 
Trypan blue and WST-1 results: Trypan 
blue (Figure 4) and WST-1 (Figure 5) 
showed significantly increased number of 
dead cells in the cell lines after the 
treatments in compare with the untreated 
control cells. The differences between the 







Figure 2. K562 and Daudi cell lines were treated with platelets (plt) or thrombin-activated platelets (aplt), in the 
24-well culture plates. Higher expression of CD95 was shown in the treatment groups compared with the control 








































Figure 3. Active caspase-3 levels in K562 and Daudi cell lines after treatment with platelets (plt) or thrombin-
activated platelets (aplt). Higher concentrations of caspase-3 were shown because of the platelets (plt) or 





Figure 4. Trypan blue results. Plasma membrane of non-viable cells was permeable to trypan blue whereas live 
cells remained unstained. The number of viable and dead cells was counted microscopically after treatment with 
platelets (plt) or thrombin-activated platelets (aplt). The percent of dead cells was calculated.  Data were 








































Figure 5. WST-1 results. Enzymatic cleavage of the tetrazolium salt (WST-1) to formazan by cellular 
mitochondrial dehydrogenases was measured with absorbance reading at the wavelength of 450 nm. Exposure 
with plts or thrombin-activated platelets (aplt) caused lower viability and metabolic activity of the cell lines. 
Data were presented as the mean±SD of five independent experiments. * Indicates P<0.05. 
Discussion 
Despite the role of platelets in tumor 
spread in the body (18), the cancer  killing 
effects of platelets has been identified for 
some cell lines (15,19).  We studied the 
viability and apoptosis of cell lines after 
co-culture with platelets or thrombin-
activated platelets. The results indicated 
that both platelets and thrombin-activated 
platelets could cause growth inhibition and 
apoptosis in the K562 and Daudi cells after 
48 hours of co-culture. 
Our study with K562 and Daudi cells were 
correlated with the studies of some 
researchers. Examples: Kawamura and co-
workers showed that platelets have roles in 
cell growth inhibition and killing of some 
neoplasm cells (20). Ible and co-workers 
showed that the produced materials in the 
arachidonate metabolism pathway of 
platelets were toxic for some tumor cell 
lines (15). Bykovskaya and co-workers 
demonstrated that platelets isolated from 
the blood of oncology patients as well as 
healthy people can cause cytotoxic effects 
on several types of tumor cell lines (21).  
However, the findings of this study were 
disagreed with that of Wang who claimed 
that the inhibition of tumor cell growth by 
platelets was mainly due to the cell cycle 
arrest and not apoptosis or cell death (17). 
We also showed that the thrombin-
activated platelets and unstimulated 
platelets both have nearly similar 
influences on tumor cell lines. Correlated 
with us, Sagawa and co-workers reported 
that the thrombin-activated platelets such 
as unstimulated platelets have cytotoxic 
effects on some tumor cell lines but due to 
different morphological changes made in 
tumor cells, their effects may be carried 
out with different mechanisms (16). 
The present study showed high expression 
levels of CD95 (FAS) on the studied cells 
after treatment with platelets or thrombin-
activated platelets. This effect may be 
related to soluble or cell surface CD40L on 
platelets. It has been found that CD40-
CD40L ligation, up regulates Fas 
expression on tumor cells (22, 23) and 
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predispose cells to apoptosis (24).On the 
contrary, Gogstad showed that the 
supernatant of thrombin-activated platelets 
had no cytotoxic effects on tumor cells 
although it contained various soluble 
materials that are secreted from activated 
platelets (25). 
The results of this study showed similarity 
between the effects of platelets and 
thrombin-activated platelets on cancer 
cells. We described the apoptotic cell 
death effects of unstimulated platelets and 
thrombin-activated platelets on K562 and 
Daudi cells for the first time. This study 
implied the capability of platelets or plt-
derived components in growth inhibition 
of some tumor cells under the appropriate 
conditions. Further studies are needed to 
clear the effective factors of platelets in 
tumor growth inhibition. 
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